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The extracellular gate shapes the energy proﬁle
of an ABC exporter
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ABC exporters harness the energy of ATP to pump substrates across membranes.
Extracellular gate opening and closure are key steps of the transport cycle, but the underlying
mechanism is poorly understood. Here, we generated a synthetic single domain antibody
(sybody) that recognizes the heterodimeric ABC exporter TM287/288 exclusively in the
presence of ATP, which was essential to solve a 3.2 Å crystal structure of the outward-facing
transporter. The sybody binds to an extracellular wing and strongly inhibits ATPase activity
by shifting the transporter’s conformational equilibrium towards the outward-facing state, as
shown by double electron-electron resonance (DEER). Mutations that facilitate extracellular
gate opening result in a comparable equilibrium shift and strongly reduce ATPase activity and
drug transport. Using the sybody as conformational probe, we demonstrate that efﬁcient
extracellular gate closure is required to dissociate the NBD dimer after ATP hydrolysis to
reset the transporter back to its inward-facing state.
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ABC exporters are versatile membrane proteins found in allphyla of life. Type I exporters are the best studied class ofABC exporters and minimally consist of two transmem-
brane domains (TMDs) each comprising six transmembrane
helices and two nucleotide binding domains (NBDs) that are
universally conserved among all ABC transporters. The NBDs
undergo large conformational changes in response to ATP
binding and hydrolysis, which are transmitted to the TMDs via
coupling helices to assume inward-facing (IF), outward-facing
(OF), and outward-occluded (Occ) conformations1. Alternating
access at the TMDs in conjugation with afﬁnity changes towards
the transported substrates enable uphill transport across the lipid
bilayer2. Fully closed NBDs are stabilized by two ATP molecules
bound at the dimer interface and coincide with TMDs adopting
an OF or Occ state3,4. The transition to the IF state requires the
NBDs to separate at least to some degree, a process that is
initiated by ATP hydrolysis5.
Many ABC exporters including the entire human ABCC family
exhibit asymmetric ATP binding sites, namely a degenerate site
that can bind but not hydrolyze ATP and a consensus site that is
hydrolysis-competent6. Heterodimeric TM287/288 of the ther-
mophilic bacterium Thermotoga maritima was the ﬁrst structu-
rally analyzed example of an ABC exporter with a degenerate
site7,8. Two closely related IF structures of TM287/288 were
solved by X-ray crystallography either containing one AMP-PNP
molecule bound to the degenerate site or no nucleotide. In con-
trast to most other IF structures of ABC exporters, the opened
NBDs of TM287/288 are only partially separated due to contacts
mediated by the degenerate site D-loop, whereas the consensus
site D-loop was found to allosterically couple ATP binding at the
degenerate site to ATP hydrolysis at the consensus site8. The
consensus site features distortions in the Walker B motif, which
prevents nucleotide binding in the IF transporter7. DEER studies
have revealed that TM287/288 exhibits dynamic IF/OF equilibria
in the presence of nucleotides and that nucleotide trapping at the
consensus site is required to strongly populate the OF state,
whereas in the presence of AMP-PNP the transporter pre-
dominantly adopts its IF state9.
Broad distance distributions were found by DEER in the
extracellular gate of TM287/288, hinting at conformational ﬂex-
ibility in this external region9. Similar observations were reported
for ABCB110. Unbiased Molecular Dynamics (MD) simulations
of TM287/288 uncovered spontaneous conformational transitions
from the IF state via an Occ intermediate to the OF state11. Many
simulations remained trapped in the Occ state, suggesting that
extracellular gate opening represents a major energetic barrier in
the conformational cycle. Interestingly, the degree of extracellular
gate opening varies greatly among different type I ABC exporters
solved in OF states, whereas the gate remains closed in the Occ
state3,4,12. Hence, events occurring at the extracellular gate likely
play a key role in substrate transport and must be allosterically
coupled to the catalytic cycle of the NBDs. Nevertheless, the
underlying molecular mechanism is unknown.
In this work, we generated single domain antibodies that
exclusively bind to OF TM287/288 and thereby inhibit the
transport cycle. The binders were instrumental to solve a crystal
structure of the transporter in its OF state and were used to probe
molecular events at the extracellular gate and their allosteric
coupling with the NBDs.
Results
Conformational trapping of TM287/288. Having solved two
closely related IF structures of TM287/288, our aim was to obtain
an atomic structure of this heterodimeric ABC exporter in its OF
state. DEER analyses revealed that TM287/288 carrying the
TM288E517Q mutation in the Walker B motif of the consensus
site (EtoQ mutation) was almost completely trapped in the OF
state in the presence of ATP-Mg or ATPγS-Mg9. To further
decrease the residual ATPase activity of the EtoQ mutant (turn-
over of 0.02 min−1) by a factor of 6.5, we instead introduced the
EtoA mutation. In addition, we generated single domain anti-
bodies (nanobodies) that exclusively recognize the OF state of
TM287/288. To this end, alpacas were immunized with OF
TM287/288 containing a cross-linked tetrahelix bundle motif13
(see Methods). This approach yielded nanobody Nb_TM#1
binding exclusively to TM287/288 in the presence (but not in the
absence) of ATP, as shown by surface plasmon resonance (SPR)
(Fig. 1d). However, crystals obtained with Nb_TM#1 did not
diffract well enough to build a reliable model. Therefore, we
selected synthetic nanobodies (sybodies) against TM287/288
(EtoA) in the presence of ATP-Mg completely in vitro14.
Thereby, more than ten OF-speciﬁc sybodies were generated and
sybody Sb_TM#35 was successfully used to solve the OF structure
of TM287/288(EtoA) in the presence of ATPγS-Mg at 3.2 Å
resolution (Fig. 1a, Supplementary Table 1).
Structure of TM287/288-sybody complex. Sybody Sb_TM#35
binds on top of an extracellular wing of TM287/288 (Fig. 1a)
and was crucially involved in establishing crystal contacts
(Supplementary Fig. 1). Binding is mediated by aromatic residues of
all three complementarity determining regions (CDRs) of the
sybody, which are wedged between transmembrane helices (TMs) 1
and 2 of TM287 and TMs 5′ and 6′ of TM288 (Fig. 2a). Since
Sb_TM#35 only binds in the presence of ATP (Fig. 1d), we
hypothesized that it interferes with the catalytic cycle of the
transporter. Indeed, the sybody inhibited the ATPase activity of
TM287/288 in detergent (IC50 of 66.1 nM, Fig. 2b), as well as
reconstituted in nanodiscs (Supplementary Fig. 2b). Of note, inhi-
bition was less efﬁcient in nanodiscs, presumably due to impaired
epitope accessibility of the sybody in the membrane context.
Two nanobodies addressing epitopes on the NBDs. Using the
high resolution structure of OF TM287/288 for molecular
replacement and as template for model building, we solved two
additional low resolution structures (3.5–4.2 Å) of the OF trans-
porter determined in complex with alpaca nanobodies Nb_TM#1
and Nb_TM#2 (Fig. 1b, c). Nb_TM#1 speciﬁcally recognizes the
OF state and binds to the bottom of the closed NBD dimer,
occupying an epitope that is shared between NBD287 and
NBD288 (Fig. 1d). Akin to Sb_TM#35, state-speciﬁc Nb_TM#1
was found to inhibit the transporter’s ATPase activity (Fig. 2b).
Nb_TM#2 binds side-ways to NBD288 and exhibits picomolar
afﬁnity for the transporter regardless whether ATP is present or
not (Fig. 1d, Supplementary Table 2). Nevertheless, this nano-
body partially inhibits ATPase activity by around 30% already at
the lowest assayed concentration of 20 nM (Fig. 2b). Because the
TM287/288 concentration needed to be at least 8 nM to reliably
measure ATPase activity, we could not determine the IC50 value
for Nb_TM#2. A measurement artifact can be excluded, because
an unrelated control sybody did not affect the transporter’s
ATPase activity (Fig. 2b).
IF to OF transition renders TM287/288 more symmetric. The
OF structure of TM287/288 features fully dimerized NBDs that
sandwich two ATPγS-Mg molecules at the degenerate and the
consensus site (Fig. 3a, Supplementary Fig. 3). An almost iden-
tical structure (RMSD of 0.21 Å) was also obtained in the pre-
sence of ATP-Mg (Supplementary Fig. 4c, Supplementary
Table 1). In contrast to the NBDs of IF TM287/288, which
exhibited pronounced asymmetries between degenerate and
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consensus site mainly with regard to the D-loops8, the closed
NBD dimer of the OF transporter is more symmetric (Fig. 3a,
Supplementary Fig. 3). Further, the distortions found at the cat-
alytic dyad of the consensus site of the IF structure (E517TM288
and H548TM288) relax during the transition to the OF state and
the two key residues adopt a hydrolysis-competent arrangement
(Fig. 3b). Interestingly, two tunnels that would allow for release of
the cleaved γ-phosphate are present at the consensus site
(Fig. 3c). The TMDs consisting of two wings each encompassing
six transmembrane helices donated from both protomers are
widely opened towards the outside (Supplementary Fig. 4). With
an RMSD of 1.73 Å, the structure of TM287/288 most closely
resembles the structure of Sav1866. Furthermore, the OF struc-
ture is similar to the OF conformation of TM287/288 predicted
by MD simulations (Supplementary Fig. 5)11, although in the MD
simulations the protein was embedded in a lipid bilayer instead of
the detergent environment used for crystallization. Also the
degree of NBD closure and extracellular gate opening is highly
similar between TM287/288 and Sav1866 (Supplementary
Fig. 6a). The RMSD between TM287 and TM288 decreases from
2.55 Å to 1.98 Å as the transporter is converted from the IF to the
OF conformation, indicating that OF TM287/288 is more sym-
metric (Supplementary Fig. 6b). Whereas a similar degree of
symmetry was observed between the half-transporters of OF
ABCB1 (PDB: 6C0V, RMSD of 2.07 Å), the equivalent super-
impositions exhibit substantial asymmetries in the OF structure
of MRP1 (PDB: 6BHU, RMSD of 4.54 Å), mostly owing to
asymmetries in the TMDs (Supplementary Fig. 6b). Extracellular
gate opening is less pronounced in MRP1 and even less so in
ABCB1, and the gate remains almost completely closed in the
outward-occluded structure of McjD4 (Supplementary Fig. 6b).
Hence, structures of OF and Occ ABC exporters show their lar-
gest structural variation in the extracellular gates.
The sybody acts as a molecular clamp. Interestingly, we did not
ﬁnd steric clashes which would prevent Sb_TM#35 from binding
to the IF transporter. Hence, based on structural information
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Fig. 1 Three outward-facing structures of TM287/288 solved in complex with single domain antibody fragments. The transporters are viewed along the
membrane plane (indicated as gray rectangle). a 3.2 Å structure of TM287/288(EtoA) in complex with ATPγS-Mg and state-speciﬁc sybody Sb_TM#35.
b 3.5 Å structure of TM287/288(2xDtoA/EtoA) in complex with ATPγS-Mg and state-speciﬁc nanobody Nb_TM#1. c 4.2 Å crystal structure of
TM287/288(2xDtoA/EtoA) in complex with ATPγS-Mg and state-unspeciﬁc nanobody Nb_TM#2. d SPR analyses in the absence (upper panel) and
presence (lower panel) of ATP using immobilized TM287/288(EtoQ) as ligand and Sb_TM#35, Nb_TM#1 and Nb_TM#2 as analytes. Injected
concentrations of Sb_TM#35: 0, 9, 27, 81, 243, 729 nM; Nb_TM#1: 0, 1, 3, 9, 27, 81 nM; Nb_TM#2: 0, 0.9, 2.7, 8.1, 24.3, 72.9 nM. Kinetic analysis is shown
in Supplementary Table 2
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alone we could not explain why the sybody inhibits ATPase
activity. Therefore, we used DEER spectroscopy to unravel the
sybody’s impact on the conformational cycle.
The sybody was found to shift the transporter’s equilibrium
towards the OF state, as measured in the presence of ATP-EDTA
(arrows in Fig. 2c). Pronounced effects were observed in the
extracellular region (54TM287/290TM288 and 54TM287/271TM287),
but also when probing distances at the intracellular region of the
TMDs (131TM288/248TM288) and at the NBDs (460TM287/
363TM288) (Fig. 2c and Supplementary Fig. 7). Further, we observed
a distance increase between two spin labels positioned in the wing
underneath the sybody (54TM287/290TM288) as a result of sybody
binding (dotted vertical lines in Fig. 2c). This suggests that the
sybody acts as a wedge at the opened extracellular wing. As
expected from the lack of sybody binding to the IF state, we
observed negligible effects on the interspin distances when TM287/
288 was incubated with the sybody in the absence of nucleotides
(apo state) (Supplementary Fig. 7).
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To investigate the positioning of the bound sybody relative to
the opposite wing, we then focused on the distance between the
sybody labeled at position 71 and spin labels introduced either at
54TM287 (the sybody-binding wing) or 271TM287 (opposite wing)
of the transporter (Fig. 2d and Supplementary Fig. 8). The main
distance peak corresponding to dipolar coupling between
71Sb_TM#35 and 54TM287 was very sharp and centered at 3.8
nm, while it was somewhat broader and centered at 3.2 nm
between 71Sb_TM#35 and 271TM287 placed on the opposite wing.
Both distances were visible only in the presence of ATP, and were
in close agreement with the simulations based on the OF
structure (Supplementary Fig. 8). Both traces also contained a
distance peak at around 5.2 nm corresponding to a residual
fraction of sybody dimers in solution. In conclusion, the sybody
acts as a molecular clamp that keeps the extracellular gate open.
Conserved aspartates seal the extracellular gate. Having shown
that the sybody traps the transporter in a fully opened state, we
reasoned that mutations facilitating extracellular gate opening
would have a similar impact on the transporter’s energy land-
scape. In IF TM287/288, D41TM287 and D65TM288 placed in TM1
of the respective half-transporter establish hydrogen bonds with
backbone amides of the opposite wing (Fig. 4a). Of note, these
aspartates are conserved in bacterial ABC exporters (Fig. 4b), but
not in eukaryotic members of the family. When the aspartates
were substituted with alanines, the ATPase activity of TM287/288
decreased around three-fold for the single mutants and around
10-fold for the double mutant (henceforth called 2xDtoA mutant)
(Fig. 4c).
Using again ATP-EDTA to induce the IF to OF transition,
DEER analyses revealed an equilibrium shift towards the OF state
in the 2xDtoA mutant for all spin-labeled pairs (Fig. 4f and
Supplementary Fig. 9). The equilibrium shift was similar to that
induced by Sb_TM#35. Hence, the aspartates at the extracellular
gate constitute an energy barrier that needs to be overcome to
switch to the OF state and inﬂuence the ATPase cycle in a long-
ranged allosteric coupling connecting the extracellular gate with
the NBDs.
To probe the atomic details of the conformational dynamics
underlying the IF–OF transition, we performed MD simulations
of TM287/288 in a POPC lipid bilayer starting from the IF crystal
structure (PDB: 4Q4A), after docking a second ATP-Mg molecule
into the consensus site11 and introducing the 2xDtoA mutations
in the extracellular gate. As in our previous MD simulations of
wild-type TM287/28811, we observed spontaneous large-scale
conformational transitions from the IF conformation via an Occ
state to an OF conformation; this complete transition was
observed in 3 out of 20 independent 500 ns simulations
(Supplementary Fig. 10). Despite the limited statistics, the
transition appears to be slightly more frequent than for the
wild-type (6 out of 100 simulations11), in agreement with our
experimental results and the notion that the polar contacts of the
two aspartate residues increase the energy barrier of extracellular
gate opening. Although MD simulations and experimental data
are in agreement, we cannot exclude different results if these
rather long simulations were conducted in a lipid bilayer
containing other lipids such as for example POPE15. To assess
the stability of the OF structure reported in this work, 20
independent 400 ns simulations were carried out for both the
wild-type and the 2xDtoA mutant. Although the sybody is not
present in the simulations, the OF conformation with two bound
ATP-Mg molecules is very stable and merely ﬂuctuates around
the X-ray structure (Supplementary Fig. 11). Additional control
simulations in a POPE (instead of POPC) bilayer conﬁrmed this
result (Supplementary Fig. 11), rendering it unlikely that lipid
composition (in terms of PC vs. PE head groups) has a large effect
on the ATP-Mg-bound OF structure.
Next, we introduced the 2xDtoA mutations into the hetero-
dimeric ABC exporter EfrEF of Enterococcus faecalis (Fig. 4b)16.
Ethidium-stimulated ATPase activity proﬁles of membrane
reconstituted EfrEF were found to be strongly affected by the
single DtoA mutations, and the ATPase activity of EfrEF
containing the 2xDtoA mutations could no longer be
stimulated by the drug (Fig. 4d). Supporting this notion, the
TM287/288(2xDtoA) mutant reconstituted in nanodiscs exhib-
ited strongly diminished drug stimulation by Hoechst 33342
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(Supplementary Fig. 2a). Next, we expressed EfrEF wild-type and
DtoA mutants in Lactococcus lactis and monitored ethidium
uptake by ﬂuorescence measurements (Fig. 4e). Wild-type EfrEF
efﬁciently expels ethidium from the cell, resulting in a slow
increase of ethidium accumulation that reaches a low steady-state
level. EfrEF containing the EtoQ mutation in the NBDs served as
negative control exhibiting high ethidium accumulation levels17.
The single DtoA mutants D41AEfrE and D50AEfrF partially lost
their capability of ethidium efﬂux. Interestingly, the accumulation
curve of the 2xDtoA mutant does not reach a steady-state level
within the time frame of the experiment. This observation
suggests a transporter defect resulting in passive inﬂux of
ethidium into the cell mediated by EfrEF carrying the 2xDtoA
mutations. In conclusion, the extracellular aspartates are
important gate-keeper residues that are allosterically coupled to
the NBDs and are required for substrate transport.
Extracellular gate mutant and sybody are synergistic. Because
both sybody binding and weakening of the extracellular gate
shifted the conformational equilibrium towards the OF state, we
reasoned that these effects are additive. Indeed, with an IC50 of
18.4 nM (Fig. 4g), inhibition of TM287/288 carrying the 2xDtoA
mutations by Sb_TM#35 was found to be more pronounced than
the inhibition of the wild-type transporter (IC50= 66.1 nM)
(Fig. 2b). In further agreement, the afﬁnity of Sb_TM#35 towards
the 2xDtoA mutant (KD= 14 nM) was around eight times higher
than towards the wild-type transporter (KD= 110 nM) (Supple-
mentary Fig. 12, Supplementary Table 2). Afﬁnity was as well
increased upon introduction of the EtoA or EtoQ mutation into
the consensus site of the transporter (KD= 66 nM) which as well
exhibit a conformational equilibrium shift towards the OF state9
and was highest for the combined triple mutant (2xDtoA/EtoA)
(KD= 8 nM). An analogous pattern was observed for Nb_TM#1,
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which binds to the closed NBD dimer. The IC50 was substantially
smaller when probing the 2xDtoA mutant (KD= 16.8 nM)
compared to wild-type TM287/288 (KD= 460 nM) (Fig. 2b,
Fig. 4g). This difference was again reﬂected by an afﬁnity increase
for the 2xDtoA mutant (37 nM) vs. the wild-type transporter
(KD= 184 nM) and the highest afﬁnity was observed for the triple
mutant (KD= 5 nM) (Supplementary Fig. 12, Supplementary
Table 2). In conclusion, Sb_TM#35 and Nb_TM#1 bind to the
opposite ends of the transporter but nevertheless exhibit a highly
similar biophysical behavior of trapping the OF transporter.
Probing the OF–IF conversion by state-speciﬁc binders. We
ﬁnally tested whether the state-speciﬁc nanobodies could be
used as probes in SPR to investigate the OF–IF transition of
TM287/288. When immobilized TM287/288(EtoA) was charged
with ATP-Mg and subsequently washed with buffer devoid of
nucleotides, the maximal SPR binding signal for the OF state-
speciﬁc binders Sb_TM#35 and Nb_TM#1 slowly decreased
over a time window of several hours (Fig. 5a). Immobilized
TM287/288 was stable within this time frame, because the max-
imal binding signal for the state-unspeciﬁc nanobody Nb_TM#2
only slightly decreased (Fig. 5a). Subsequently, we interrogated
the OF–IF conversion using either ATP-Mg (hydrolyzing con-
ditions) or ATP-EDTA (ATP binding without hydrolysis).
In the case of wild-type TM287/288 loaded with ATP-Mg or
ATP-EDTA, the state-speciﬁc binders were unable to recognize
the transporter within the time resolution of the experiment,
showing rapid conversion to the IF state. In contrast, the OF state
was long-lived when ATP-Mg was occluded by the EtoQ or the
EtoA mutant. The lifetime of the OF state as probed by the state-
speciﬁc binders Sb_TM#35 or Nb_TM#1 was highly similar (t1/2
of 45 or 49 min for the EtoQ mutant and 287 or 268 min for the
EtoA mutant, respectively). Strikingly, these values are in close
agreement with the half-life of ATP hydrolyzed by these mutants,
namely 32 min (EtoQ mutant) and 205 min (EtoA mutant) at
25 °C. For the same mutants, the situation was inversed for ATP-
EDTA. The EtoA mutant readily converted to the IF state akin to
the wild-type transporter, whereas the OF state was very stable for
the EtoQ mutant (t1/2= 112 or 95 min, respectively). In this case,
ATP cannot be hydrolyzed and we investigate NBD dissociation
with bound ATP (but lacking the coordination by Mg2+). The
glutamine in the Walker B motif appears to stabilize ATP binding
in the NBD sandwich dimer, whereas the canonical glutamate or
an alanine at the same position promotes fast NBD dissociation.
When the 2xDtoA mutations were introduced, the OF state was
very long-lived in case of ATP-EDTA (t1/2= 297 or 281 min,
respectively). This suggests that weakening of the extracellular
gate by the 2xDtoA mutations strongly impedes NBD dissocia-
tion, whereas NBD dissociation of the wild-type transporter is
very fast under these experimental conditions. NBD opening is
further slowed down if the 2xDtoA mutations are combined with
the EtoA mutation for both ATP-Mg and ATP-EDTA.
From this dataset one can draw two major conclusions. First,
ATP hydrolysis weakens the NBD dimer and is required to reset
the transporter to the IF state under physiological conditions
where ATP and Mg2+ are always present. And second, strong
contacts at the extracellular gate are mandatory to exert a
mechanical force onto the NBDs to facilitate fast NBD opening in
order to reset the transport back to its IF state.
Discussion
In this work we unleashed the power of state-speciﬁc single
domain antibodies obtained from alpacas and entirely in vitro
from synthetic libraries to investigate a membrane transporter
at the structural and functional level. The strategy of generating
state-speciﬁc binders against type I ABC exporters has a long
history going back to the 90’s of the last century, when the
state-speciﬁc ABCB1 antibody UIC2 was identiﬁed18. A recent
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cryo-EM structure of ABCB1 in complex with UIC2 revealed
that the antibody clamps the extracellular loops together,
thereby preventing extracellular gate opening19. Molecular
clamping of the closed extracellular gate was also achieved by
a cyclic peptide raised against CmABCB120. Further
examples of binders that prevent the IF–OF conversion are
nanobodies raised against ABCB1 and PglK, which both steri-
cally clash with NBD closure21,22. In contrast, our binders are
speciﬁc for the OF state and consequently impede the OF–IF
conversion.
Sybody binding to an extracellular wing of TM287/288 was
essential to solve the OF structure. Both the degenerate and the
consensus ATP binding site are fully closed and highly sym-
metric, but only the consensus site bears the catalytic dyad
positioned to catalyze ATP hydrolysis23. This suggests that ATP
hydrolysis of only one nucleotide is sufﬁcient to initiate dis-
sociation of the NBDs. In further support of this view, the closed
NBD dimers features two possible Pi exit tunnels at the
consensus site.
A comparison with other OF and Occ transporter struc-
tures revealed major conformational heterogeneity in the degree
of extracellular gate opening, which has been discussed to play a
potential role in squeezing out substrates or to prevent rebinding
of substrates3,4,10,12,24. In this study, we uncover cross-talk
between the extracellular gate and the ATPase cycle, a connection
that has to the best of our knowledge not yet been investigated at
the molecular level (Fig. 6). A sybody stabilizing the opened
extracellular wing or mutations weakening the extracellular gate
both shifted the conformational equilibrium towards the OF state.
Previous experimental and computational studies have uncovered
that NBD closure precedes extracellular gate opening during the
IF–OF transition11,25, and DEER analyses have revealed that
extracellular gate opening can be partial while NBD closure is
complete9,10,26. Hence, there seems to be an inbuilt mechanical
principle that the extracellular gate is energetically costly to open.
Conversely, using our state-speciﬁc nanobodies as conformational
probes we were able to show that extracellular gate closure is
coupled to the dissociation of the closed NBD dimer after ATP
hydrolysis. Our experiments on EfrEF demonstrated that a ﬁrmly
sealed extracellular gate is in fact crucial for transporter function.
Further, the 2xDtoA mutant had a strongly reduced ATPase
activity and lost its capacity to be stimulated by drugs. This
suggests that extracellular gate closure has become the rate-
limiting step of the catalytic cycle of the 2xDtoA mutant. Hence,
in this mutant the IF–OF conversion is no longer rate-limiting
and consequently cannot be stimulated by drug binding to the
inward-oriented high-afﬁnity site (Fig. 6).
The ATP-bound OF state with completely closed NBDs has
been referred to as the high-energy state of the transport cycle
and in some instances it was proposed that ATP hydrolysis is
needed to populate the OF state at all10,26. In contrast, we and
others have previously stipulated that ATP binding alone is suf-
ﬁcient for IF–OF conversion and substrate release9,11,27, in
agreement with the ATP-switch model28. It should be noted that
while the opened extracellular gate indeed represents a high-
energy state, the opposite is in fact true for the closed NBD dimer.
It adopts a low-energy state and a large energy input is required
to dissociate the dimer29. This is certainly achieved in part by the
hydrolysis of ATP30,31. Importantly, our results suggest that NBD
dissociation also involves a mechanical component mediated by
extracellular gate closure. A further possibility is the triggering of
ATP hydrolysis as a result of extracellular gate closure. Although
speculative and neither directly supported nor excluded by our
data, such a mechanism would assure that the transporter only
reverts to the IF state after substrate release.
Why and when ATP hydrolysis is required to achieve active
transport is a recurrent debate in the ABC transporter ﬁeld. Our
data presented here and in previous studies9,11 clearly suggest
that ATP binding alone (in case of ATP-EDTA when ATP
hydrolysis cannot occur) is sufﬁcient for the IF–OF conversion
and presumably the active transport of one substrate molecule.
Directionality of transport is then achieved by an afﬁnity switch
of the substrate binding site, which inevitably undergoes drastic
rearrangements as the TMDs switch from an IF to an OF con-
formation12. Nevertheless, it is unlikely that an ABC exporter can
operate efﬁciently by binding and dissociation of ATP alone,
because energy input is lacking and the molecular events would
be driven by slow stochastic Brownian motions alone. To strongly
populate the OF state under physiological conditions, ATP-Mg
needs to be occluded at the consensus site of the closed NBD
dimer32, a state that can be efﬁciently mimicked by the Walker B
EtoQ or EtoA mutation33. As we show here with our binder
probes, ATP occlusion ﬁrmly traps the transporter in the OF state
and prevents transporter cycling. Hence, ATP hydrolysis appears
to be strictly required to initiate dissociation of the closed NBD
dimer. Once ATP is hydrolyzed, the force exerted by the closed
extracellular gate facilitates NBD dissociation. In summary, our
results support the notion that ATP hydrolysis is required to
drive the transport cycle at the resetting step from the OF to the
IF state.
We hope that our results provide a mechanistic framework to
further study the functional role of the extracellular gate of type I
ABC exporters and to investigate the molecular underpinning
of disease-causing mutations found in the extracellular region
of medically important ABC exporters such as MRP1 and
CFTR34,35.
Methods
Expression and puriﬁcation. The genes encoding the heterodimeric ABC trans-
porter TM287/288 were ampliﬁed and cloned into pINIT_cat (addgene: Plasmid
#46858)7.The genes were subcloned into pBAD expression vectors by FX cloning;36
1 ATP
1 ADP
D D
D D
1 Pi
(1)
(2)
(3)
Fig. 6 Role of the extracellular gate in the transport cycle of TM287/288.
Substrate (yellow star) binds to the IF transporter (1) with high afﬁnity,
while the extracellular gate is sealed by two aspartates (closed D-lock).
Binding and occlusion of two ATP-Mg molecules at the NBD interface
drives the transition to the OF state (2). The extracellular gate opens (open
D-lock) and substrate is released. The extracellular gate of the empty
outward-oriented cavity closes (3) and thereby may trigger ATP hydrolysis
at the consensus site. The mechanical force of the ﬁrmly sealed
extracellular gate (closed D-lock) is required to dissociate the NBDs after
ATP hydrolysis in order to reset the transporter to its IF state
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for crystallization and biochemical analyses into the pBXNH3L expression vector
or into the pBXNH3LCA expression vector for the production of biotinylated
TM287/288 variants14.
Freshly transformed MC1061 E. coli cells were grown in Terriﬁc Broth (TB)
medium, supplemented with 100 µg/ml ampicillin, to an OD600 of 1.0–1.5 at 37 °C
and expression was induced by the addition of 0.0017 % (w/v) L-arabinose for 5 h at
30 °C. Cells were harvested and cellular membranes prepared in 20mM Tris-HCl
pH 7.5, 200mM NaCl and 10 % (v/v) glycerol. Membranes were solubilized by the
addition of 1 % (w/v) n-dodecyl-β-D-maltoside (β-DDM, Glycon) for 2 h at 4 °C.
Solubilized membranes were supplemented with 20 mM imidazole and loaded on a
Ni-NTA Superﬂow (Qiagen) gravity ﬂow column at 4 °C, washed with 20 column
volumes 50 mM imidazole pH 7.5, 200 mM NaCl, 10 % (v/v) glycerol and 0.03 %
(w/v) β-DDM or 0.3 % (w/v) n-decyl-β-D-maltoside (β-DM, Glycon) and eluted
with 4 column volumes 200 mM imidazole pH 7.5, 200 mM NaCl, 10 % (v/v)
glycerol and 0.03 % (w/v) β-DDM or 0.3 % (w/v) β-DM, followed by desalting
using a PD-10 column (GE Healthcare, 17–0851–1) equilibrated with 20mM Tris-
HCl pH7.5, 150mM NaCl and 0.03 % (w/v) β-DDM or 0.3 % (w/v) β-DM. The
His10-tag was cleaved off overnight at 4 °C using 3 C protease (1:10 w/w), followed
by reloading on a Ni-NTA gravity ﬂow column equilibrated with 20 mM Tris-HCl
pH 7.5, 150 mM NaCl, 40 mM imidazole and 0.03 % (w/v) β-DDM or 0.3 % (w/v)
β-DM at 4 °C. Processed TM287/288 was polished by size-exclusion
chromatography using a Superdex 200 Increase 10/300 GL (GE Healthcare)
column equilibrated in 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.03 % (w/v) β-
DDM or 0.3 % (w/v) β-DM at 4 °C and concentrated to the desired concentration
with an Amicon Ultra-4 concentrator unit with a molecular weight cut-off
(MWCO) of 50 kDa. Puriﬁed TM287/288 variants were used immediately or ﬂash-
frozen in liquid nitrogen and stored at −80 °C.
Avi-tagged TM287/288 variants were enzymatically biotinylated using BirA
during 3 C cleavage in 20 mM imidazole pH 7.5, 200 mM NaCl, 10 % (v/v) glycerol,
10 mM magnesium acetate and 0.03 % (w/v) β -DDM, and two-fold molar excess
of biotin.
EfrEF was ampliﬁed from the genomic DNA of Enterococcus faecalis V583,
cloned into the shuttle vector pREXNH3 via FX cloning36 and subcloned into the
expression vector pNZ8048NH3 via vector backbone exchange cloning (VBEx)37.
Transformed L. lactis NZ9000 ΔlmrAΔlmrCD cells38 were grown in M17 medium
supplemented with 0.5% glucose and 5 µg/ml chloramphenicol to an OD600 of 1 at
30 °C and the expression was induced by adding a nisin-containing culture
supernatant of L. lactis NZ9700 for 4 h (1:5000 [v/v]). Cells were harvested and
membranes were prepared in 20 mM Tris-HCl pH 7.5, 200 mM NaCl and 10 %
(v/v) glycerol16. EfrEF was puriﬁed using β-DDM in the same way as TM287/288
(see above).
Nanobodies/sybodies were either expressed from pSb_init (addgene:
#110100) for biochemical experiments or subcloned into pBXNPHM3 (addgene:
#110099) by FX cloning for the production of tag-free nanobodies/sybodies for
crystallization and DEER experiments14,36. Puriﬁed nanobodies and sybodies were
stored at −80 °C.
Mutagenesis. To weaken the extracellular gate, two conserved aspartates were
replaced by alanines in various TM287/288 variants resulting in TM287/288
(2xDtoA). D41ATM287 was introduced using the primers TM287_D41A_FW
(GGC ACG TAT TGT CGC CGA AGG AAT CG C) and TM287_D41A_RV
(GCG ATT CCT TCG GCG ACA ATA CGT GCC). D65ATM288 was introduced
using the primers TM288_D65A_FW (CAT AGG AAA AAC GAT CGC TGT
TGT CTT CG) and TM288_D65A_RV (CGA AGA CAA CAG CGA TCG TTT
TTC CTA TG). In order to render TM287/288 catalytically inactive, E517ATM288
was introduced in wild-type TM287/288 and TM287/288(2xDtoA) using the pri-
mers TM288_E517A_FW (CCT GAT ACT GGA CGC AGC CAC CAG CAA C)
and TM288_E517A_RV (GTT GCT GGT GGC TGC GTC CAG TAT CAG G).
Mutation D41AEfrE was introduced using the primers EfrE_D41A_FW (CAA GTT
GAT TGC TGT GGG CAT CG) and EfrE_D41A_RV (CGA TGC CCA CAG CAA
TCA ACT TG). D50AEfrF was generated using the primers EfrF_D50A_FW (CAA
TCG GGA TTG CTA ACC TCT TAG AAG C) and EfrF_D50A_RV (GCT TCT
AAG AGG TTA GCA ATC CCG ATT G). In order to cross-link the transporter at
the tetrahelix bundle in the OF state, L200CTM287 was introduced in cys-less
TM287/288 (described in ref. 7) using the primers TM287_L200C_FW (GAG AAA
ATC TCT GCG GTG TCA GGG TAG TGA G) and TM287_L200C_RV (CTC
ACT ACC CTG ACA CCG CAG AGA TTT TCT C) and combined with the
S224CTM288 mutation using the primers TM288_S224C_FW (CAT AGA AGA
AGA CAT CTG CGG CCT CAC TGT G) and TM288_S224C_RV (CAC AGT
GAG GCC GCA GAT GTC TTC TTC TAT G).
For spin labeling of the sybody, S71C was introduced in Sb_TM#35 using the
primers Sb_TM#35_S71C_FW (CAC GGT GTG CCT GGA CAA CG) and
Sb_TM#35_S71C_RV (CGT TGT CCA GGC ACA CCG TG).
For spin labeling of TM287/288, three new cysteines were introduced in cys-less
TM287/288 (called wild-type TM287/288 for simplicity). S271CTM287 was
generated using the primers TM287_S271C_FW (CAG ATG GAG ATA GGA
TGC ATC ATG GCA TAC) and TM287_S271C_RV (GTA TGC CAT GAT GCA
TCC TAT CTC CAT CTG) as a single mutant or in combination with K54CTM287,
which was generated using the primers TM287_K54C_FW (CTT TTC TCT GGT
TTT GTG TAC AGG GAT CCT CAT G) and TM287_K54C_RV (CAT GAG GAT
CCC TGT ACA CAA AAC CAG AGA AAA G). K54CTM287 was also prepared as
a single mutant or in combination with I290CTM288 introduced with the primers
TM288_I290C_FW (CGC CTT GAA AGA CTG TAT CAC GGT GGG) and
TM288_I290C_RV (CCC ACC GTG ATA CAG TCT TTC AAG GCG).
Puriﬁed mutant proteins were all analyzed by SEC and did not differ in terms of
elution proﬁle and yield from the wild-type transporter.
Crystallization. For crystallization of TM287/288(EtoA) or TM287/288(2xDtoA/
EtoA) in complex with Sb_TM#35, freshly puriﬁed transporter in 0.3% (w/v) β-
DM was concentrated to about 12 mg/ml using an Amicon Ultra-4 concentrator
unit (50 kDa MWCO) and puriﬁed Sb_TM#35 (stored at −80 °C) was added in a
1.1-fold molar excess (ﬁnal complex concentration of 10 mg/ml). Complexes were
pre-incubated with 2.5 mM adenosine 5′-(3-thiotriphosphate) (ATPγS, Sigma,
A1388) or 5 mM ATP, 3 mM MgCl2 for 5–6 days at 20 °C (without this incubation
step, the crystals did not diffract to high resolution), before crystals were grown by
the vapor diffusion method in sitting drops (1:1 protein to reservoir ratio) at 20 °C.
Crystals were picked from wells containing either 0.1 M Na-acetate pH 4.6, 0.035M
NaCl and 11.5% (w/v) PEG6000 (ATPγS-bound structure), or 0.1 M Na-acetate pH
4.6, 0.025M NaCl and 12% (w/v) PEG6000 (ATP-bound structure). Crystals
appeared within 1–3 days and were ﬁshed immediately. Crystals were cryo-
protected in 0.1 M Na-acetate pH 4.6, 0.04 M NaCl and 15% (w/v) PEG6000
additionally containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.3% (w/v) β-DM,
3 mM MgCl2, 1.25 mM ATPγS, or 5 mM ATP and 25% (v/v) ethylenglycol and
ﬂash-frozen in liquid nitrogen.
For crystallization of TM287/288(2xDtoA/EtoA) in complex with Nb_TM#1,
puriﬁed Nb_TM#1 (stored at −80 °C) was added to the transporter puriﬁed in
0.3% (w/v) β-DM in a 1.2-fold molar excess prior to size-exclusion
chromatography. After short incubation on ice, the complex was separated from
excess nanobodies by size-exclusion chromatography using a Superdex 200
Increase 10/300 GL (GE Healthcare) column equilibrated in 20 mM Tris-HCl pH
7.5, 150 mM NaCl, and 0.3% (w/v) β-DM. The transporter/nanobody complexes
were concentrated to 10 mg/ml using an Amicon Ultra-4 concentrator unit (50 kDa
MWCO) and incubated with 5 mM ATPγS and 3 mM MgCl2 for 15 min on ice.
Crystals were grown by the vapor diffusion method in sitting drops (1:1 protein to
reservoir ratio) at 20 °C in 0.05 M Glycine pH 9.5, 0.225 M NaCl and 21% (v/v)
PEG550MME. Crystals appeared within 2–3 days and were grown for another
3 weeks. Crystals were cryo-protected in reservoir solution containing 10% (v/v)
PEG400 and ﬂash-frozen in liquid nitrogen.
For crystallization of TM287/288(2xDtoA/EtoA) in complex with Nb_TM#2,
puriﬁed Nb_TM#2 (stored at −80 °C) was added to the transporter puriﬁed in
0.03% (w/v) β-DDM in a 1.2-fold molar excess prior to size-exclusion
chromatography. After short incubation on ice, the complex was separated from
excess nanobodies by size-exclusion chromatography using a Superdex 200
Increase 10/300 GL (GE Healthcare) column equilibrated in 20 mM Tris-HCl pH
7.5, 150 mM NaCl, and 0.03% (w/v) β-DDM. The transporter/nanobody complexes
were concentrated to 10 mg/ml using an Amicon Ultra-4 concentrator unit (50 kDa
MWCO) and incubated with 2.5 mM ATPγS and 3 mM MgCl2 for 15 min on ice.
Crystals were grown by the vapor diffusion method in sitting drops (1:1 protein to
reservoir ratio) at 20 °C in 0.1 M Tris-HCl pH 8.5, 0.1 M NaCl and 30% (v/v)
PEG400. Crystals appeared within 2–3 days and were grown for another 2–3 weeks.
Crystals were ﬂash-frozen in liquid nitrogen without further cryo-protection.
Data collection and structure determination. Diffraction data were collected
with a wavelength of 1.0 Å at 100 K at the beamlines X06DA and X06SA at the
Swiss Light Source (SLS, Villigen, Switzerland). Diffraction data were processed
with the program XDS39 and truncated using the Diffraction Anisotropy Server
with default settings40 due to strong or severe anisotropy, what lead to improved
electron density maps (Supplementary Table 1, Supplementary Fig. 13).
The TM287/288(EtoA) – Sb_TM#35 – ATPγS-Mg complex structure was
solved by molecular replacement in Phaser41 using a modiﬁed homology model
based on Sav1866 (PDB: 2HYD). The crystals belong to the space group P21
containing two TM287/288 heterodimers and two sybodies per asymmetric unit.
After a few cycles of model building in Coot42 and reﬁnement in Buster (www.
globalphasing.com), a poly-alanine model of a nanobody (PDB: 1ZVH) was
manually placed into additional electron density. Multiple iterations of model
building in Coot and TLS reﬁnement in Buster resulted in a ﬁnal model with good
geometry (Ramachandran favored/outliers: 96.54%/0.08%) (Supplementary
Table 1). Chains A (TM287), B (TM288) and E (Sb_TM#35) were used for
structural analysis and ﬁgures.
In order to determine the TM287/288(2xDtoA/EtoA) – Sb_TM#35 – ATP-Mg
complex structure, the ﬁnal TM287/288(EtoA) – Sb_TM#35 – ATPγS-Mg complex
structure was used for reﬁnement against the TM287/288(2xDtoA/EtoA) –
Sb_TM#35 – ATP-Mg data. The 2xDtoA mutations were introduced and the
ATPγS replaced by ATP in Coot. TLS reﬁnement in Buster resulted in a ﬁnal
model with good geometry (Ramachandran favored/outliers: 96.58%/0.24%)
(Supplementary Table 1). Chains A (TM287) and B (TM288) were used for
structural comparison with the TM287/288(EtoA) – Sb_TM#35 – ATPγS-Mg
complex structure.
The TM287/288(2xDtoA/EtoA) – Nb_TM#1 – ATPγS-Mg complex structure
was solved by molecular replacement in Phaser using the TM287/288(EtoA) –
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Sb_TM#35 structure without the sybody. The crystals belong to the space group
P21 containing two TM287/288 heterodimers and two nanobodies per asymmetric
unit. After some cycles of model building in Coot and reﬁnement in Buster, Phaser
was used to place the missing nanobody using a homology model based on PDB
entry 5OCL. Multiple iterations of model building in Coot and TLS reﬁnement in
Buster resulted in a ﬁnal model with good geometry (Ramachandran favored/
outliers: 94.68%/0.24%) (Supplementary Table 1). Chain A (TM287), B (TM288)
and E (Nb_TM#1) were used for ﬁgures.
The TM287/288(2xDtoA/EtoA) – Nb_TM#2 – ATPγS-Mg complex structure
was solved by molecular replacement in Phaser using the TM287/288(EtoA) –
Sb_TM#35 structure without the sybody. The crystals belong to the space group P1
containing two TM287/288 heterodimers and two nanobodies per asymmetric unit.
After several cycles of model building in Coot and reﬁnement in Buster, Phaser was
used to place the missing nanobody using a poly-alanine homology model based on
PDB entry 4LAJ. Multiple iterations of model building in Coot and TLS reﬁnement
in Buster resulted in a ﬁnal model at 4.2 Å resolution (Ramachandran favored/
outliers: 93.34%/0.83%) (Supplementary Table 1). Chain A (TM287), B (TM288)
and E (Nb_TM#2) were used for ﬁgures. Molecular graphics and analyses were
performed in Pymol or with UCSF Chimera43.
ATPase assays. ATPase activities were measured by detecting liberated phosphate
using molybdate/malachite green method. To detect phosphate, reaction solution
(90 μl) was mixed with ﬁltrated malachite green detection solution (160 μl) con-
sisting of 10.5 mg/mL ammonium molybdate, 0.5 M H2SO4, 0.34 mg/ml malachite
green, and 0.1% Triton X-100, and absorption was measured at 650 nm8. ATPase
activity measurements with detergent-puriﬁed protein were carried out in ATPase
buffer consisting of 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM MgSO4
containing 0.03% (w/v) β-DDM. Activity measurements of TM287/288 recon-
stituted in nanodiscs were performed in the same buffer lacking detergent. Mea-
surements of EfrEF reconstituted in proteoliposomes were carried out in 50 mM
HEPES pH 7.0 and 10 mM MgSO4.
Relative ATPase activities of TM287/288(D41ATM287), TM287/288
(D65ATM288), and TM287/288(2xDtoA) compared to wild-type TM287/288 were
measured at 25 °C for 15 min in the presence of 500 µM ATP. 32 nM wild-type
TM287/288, 64 nM single DtoA TM287/288 variants and 128 nM TM287/288
(2xDtoA) were used and the respective concentration of TM287/288(EtoQ) for
background subtraction.
The relative ATPase activity stimulations of EfrEF variants in proteoliposomes
by ethidium were determined at 30 °C for 15 min in the presence of 1 mM ATP.
The amount of reconstituted EfrEF variants was determined by quantitative SDS-
PAGE. 4 nM wild-type EfrEF, 23 nM single DtoA EfrEF variants, and 15 nM EfrEF
(2xDtoA) were used and buffer controls were taken for background subtraction.
Inhibition of ATPase activities of wild-type TM287/288 and TM287/288
(2xDtoA) in detergent by binders was determined in the presence of 500 µM ATP
at 25 °C for 30 min or 60 min, respectively. 8 nM wild-type TM287/288, as well as
TM287/288(2xDtoA) were used, which is more than 2-fold less than the lowest
binder concentration (20 nM). For background subtraction equal amounts of
TM287/288(EtoQ) were used. To obtain IC50 values, the inhibition data were ﬁtted
with a hyperbolic decay curve with the following function (SigmaPlot):
f ¼ y0 þ ða  IC50Þ= IC50 þ xð Þ ð1Þ
in which f corresponds to the ATPase activity at the respective binder
concentration divided by the ATPase activity in the absence of inhibitor
normalized to 100%, y0 corresponds to the residual activity at inﬁnite binder
concentration, a corresponds to the maximal degree of inhibition (a+ y0= 100%)
and x corresponds to the binder concentration.
Stimulated ATPase activities of wild-type TM287/288 and TM287/288(2xDtoA)
in nanodiscs were determined at 37 °C for 30 min in the presence of 500 µM ATP
and varying Hoechst 33342 concentrations. 40 nM wild-type TM287/288, as well as
TM287/288(2xDtoA) were used to determine relative stimulations compared to
basal ATPase activities using buffer for background subtraction.
Hoechst 33342 stimulated ATPase activity inhibition in nanodiscs was
determined at 37 °C for 30 min in the presence of 500 µM ATP and 50 µM Hoechst
33342. 8 nM wild-type TM287/288 and 40 nM TM287/288(2xDtoA) in nanodiscs
were used to determine ATPase activities in the presence or absence of 10 µM
binders using empty nanodiscs for background subtraction.
BMOE cross-linking. To raise alpaca nanobodies speciﬁcally recognizing the OF
state of TM287/288, the transporter was cross-linked at the tetrahelix bundle,
which forms when the transporter adopts the OF state13. Two cysteines were
introduced in the cys-less TM287/288 variant at positions L200CTM287 and
S224CTM288 by site-directed mutagenesis. On top, the 2xDtoA mutations were
introduced in TM287/288_cl_L200CTM287/S224CTM288. Since the two cysteines
are too far apart to form a disulﬁde bond, the maleimide cross-linker BMOE
(bismaleimidoethane, Thermo Scientiﬁc™, #22323) with a length of 8 Å was used.
TM287/288_cl_L200CTM287/S224CTM288 with or without the 2xDtoA mutations
was expressed as described above. Membranes were solubilized and puriﬁed by Ni-
NTA afﬁnity chromatography in presence of 1 mM dithiothreitol (DTT) in 0.03%
(w/v) β-DDM. Buffer was exchanged and DTT removed by size-exclusion chro-
matography using a Superdex 200 Increase 10/300 GL (GE Healthcare) column
equilibrated in PBS pH 7.4 and 0.03% (w/v) β-DDM at 4 °C and concentrated to
50 µM with an Amicon Ultra-4 concentrator unit with a MWCO of 50 kDa. 10 mM
ATP, 3 mM MgCl2, and a 5-fold molar excess of BMOE over transporter were
added and the cross-linking mixture incubated for 3 h at 30 °C. The mixture was
diluted 5-fold and incubated with 3 C protease (1:10 w/w) overnight at 4 °C. The
cross-linked and Tag-free transporter was reloaded on a Ni-NTA gravity ﬂow
column equilibrated with 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 40 mM imi-
dazole and 0.03% (w/v) β-DDM. The sample was concentrated with Amicon Ultra-
4 concentrator units with a MWCO of 50 kDa, 10% (v/v) glycerol was added and
aliquots were ﬂash-frozen in liquid nitrogen and stored at −80 °C ready for size-
exclusion chromatography. Cross-linked TM287/288_cl_L200CTM287/S224CTM288
with or without the 2xDtoA mutations was polished by size-exclusion chromato-
graphy using a Superdex 200 Increase 10/300 GL (GE Healthcare) column equi-
librated in 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.03% (w/v) β-DDM at 4 °C
and concentrated to 1 mg/ml with an Amicon Ultra-4 concentrator unit with a
MWCO of 50 kDa and immediately used for alpaca immunizations.
Nanobody and sybody selections. For the selection of OF state-speciﬁc nano-
bodies, an alpaca was immunized with subcutaneous injections four times in two
week intervals, each time with 200 µg puriﬁed cross-linked TM287/288(2xDtoA)
_cl_L200CTM287/S224CTM288 in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, and
0.03% (w/v) β-DDM. Immunizations of alpacas were approved by the Cantonal
Veterinary Ofﬁce in Zurich, Switzerland (animal experiment licence nr. 188/2011).
Blood was collected two weeks after the last injection for the preparation of the
lymphocyte RNA, which was then used to generate cDNA by RT-PCR to amplify
the VHH/nanobody repertoire. Phage libraries were generated and two rounds of
phage display were performed against TM287/288(2xDtoA/EtoA) solubilized in β-
DDM in the presence of 2 mM ATP-Mg. After the ﬁnal phage display selection
round, 91.9-fold enrichment was determined by qPCR using AcrB as background.
The enriched nanobody library was subcloned into pSb_init by FX cloning and
94 single clones were analyzed by ELISA in the presence of 1 mM ATP-Mg. The 27
positive ELISA hits were Sanger sequenced and grouped in three families according
to their CDR3 length and sequence (among them was Nb_TM#1). In another
selection cross-linked TM287/288_cl_L200CTM287/S224CTM288 was used for
alpaca immunizations resulting in 51 positive ELISA hits, of which 24 were Sanger
sequenced and grouped into four binder families (among them was Nb_TM#2).
Sybodies were selected against TM287/288(E517A) in β-DDM in presence of 1
mM ATP-Mg with our in vitro selection platform14. After the second round of
phage display, single clones were analyzed for binding against TM287/288(E517A)
in presence of ATP-Mg by ELISA. Sequencing of 48 ELISA positives resulted in 40
unique sybody sequences14.
Spin labeling for DEER. TM287/288 cysteine variants were expressed as described
above and puriﬁed by Ni-NTA afﬁnity chromatography in presence of 2 mM DTT.
For spin labeling, DTT was removed on a PD-10 column (GE Healthcare, 17-0851-
1) equilibrated with 20 mM Tris-HCl pH 7.5, 150 mM NaCl, and 0.03% β-DDM
and MTSL [(1-oxyl-2,2,5,5-tetramethyl-Δ3-pyrroline-3-methyl)methanethiosulfo-
nate, Toronto Research] was added in a 10-fold molar excess and incubated at 4 °C
overnight. Free spin-label was removed by size-exclusion chromatography on a
Superdex 200 Increase 10/300 GL (GE Healthcare) column equilibrated in 20 mM
Tris-HCl pH 7.5, 150 mM NaCl, and 0.03% (w/v) β-DDM at 4 °C. The samples
were concentrated to 30–50 µM with Amicon Ultra-4 concentrator units with a
MWCO of 50 kDa, ﬂash-frozen in liquid nitrogen and stored at −80 °C ready for
DEER experiments. The pairs 131TM288/248TM288 and 460TM287/363TM288 were
already used in previous studies8,9, whereas the extracellular spin-label pairs
54TM287/271TM287 and 54TM287/290TM288 were constructed as part of this study
and their ATPase activities were determined (Supplementary Table 3).
For site-speciﬁc spin labeling of Sb_TM#35, a single cysteine was introduced in
the framework of the sybody at position 71 by site-directed mutagenesis.
Sb_TM#35_S71C was expressed from pBXNPHM3 as described above. Cells were
harvested and resuspended in PBS pH 7.4 and 2 mM DTT supplemented with
DNase (Sigma) and disrupted with an M-110P Microﬂuidizer® (Microﬂuidics™).
The supernatant, supplemented with 20 mM imidazole, was loaded on a Ni-NTA
gravity ﬂow column, washed with 20 column volumes PBS pH 7.4, 50 mM
imidazole and 2 mM DTT and eluted with 4 column volumes PBS pH 7.4, 300 mM
imidazole and 2 mM DTT.
In a next step Sb_TM#35_S71C fused to His-tagged MBP was incubated with 3
C protease (1:10 w/w), while dialyzing against PBS pH 7.4 and 2 mM DTT
overnight at room temperature. Cleaved sybody was reloaded on a Ni-NTA gravity
ﬂow column and eluted with three column volumes PBS pH 7.4, 40 mM imidazole
and 2 mM DTT, followed by size-exclusion chromatography using a Sepax-
SRT10C SEC-300 (Sepax Technologies) column equilibrated with PBS pH 7.4 and
2 mM DTT. Peak fractions were collected and DTT removed using a PD-10
column (GE Healthcare, 17-0851-1) equilibrated with degassed PBS pH 7.0 at 4 °C.
To avoid DTT take-over, the sybodies were eluted with 3.2 ml degassed PBS pH
7.0, instead of the 3.5 ml suggested by the manufacturer. The elution was
concentrated to 2.5 ml using an Amicon concentrator unit with a 3 kDa MWCO. 5-
fold molar excess MTSL was added to the sample and incubated for 1 h on ice, a
condition which was previously reported to prevent labeling of the buried cysteines
that form the universally conserved disulﬁde bond of nanobodies44. Free label was
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removed and buffer exchanged using a PD-10 column (GE Healthcare, 17-0851-1)
equilibrated with 20 mM Tris-HCl pH 7.5 and 150 mM NaCl. In order to avoid
MTSL take-over, the sybodies were eluted with 3.2 ml 20 mM Tris-HCl pH 7.5 and
150 mM NaCl. Spin-labeled sybodies were concentrated to the desired
concentration with an Amicon Ultra-4 concentrator unit with a 3 kDa MWCO and
ﬂash-frozen in liquid nitrogen and stored at −80 °C. Site-speciﬁc labeling was
conﬁrmed and quantiﬁed by mass spectrometry.
DEER measurements. The labeling efﬁciency of the double cysteine mutants of the
transporters solubilized in detergent was measured by comparing the second
integral of the spectra detected at 25 °C using an X-band Miniscope 400 EPR
spectrometer (Magnettech by Freiberg Instruments) with that of a standard
TEMPOL solution in water. The calculated spin labeling efﬁciencies of the twelve
mutants ranged between 80% and 90%. For DEER measurements, 10% (v/v) D8-
glycerol was added as cryoprotectant. The range of ﬁnal transporter concentrations
was 15 to 25 µM. The sample (40 µl) was loaded in quartz tubes with 3 mm outer
diameter. The ATP-EDTA sample contained 2.5 mM ATP and 2.5 mM ethylene-
diaminetetraacetate (EDTA) to completely inhibit ATP hydrolysis; samples were
incubated at 25 °C for 10 min and snap-frozen in liquid nitrogen. For vanadate
trapping, samples were incubated with 5 mM sodium orthovanadate, 2.5 mM ATP
and 2.5 mM MgCl2 for 3 min at 50 °C and snap-frozen in liquid nitrogen. The
unlabeled Sb_TM#35 was added to the TM287/288 in ∼1.3:1 stoichiometric ratio.
To measure sybody-transporter distances, Sb_TM#35 spin-labeled at position 71
was added in a 0.5:1 stoichiometric ratio to the singly-labeled TM287/288 mutants
(54TM287 and 271TM287) in the presence of ATP-EDTA.
Double electron–electron resonance (DEER) measurements were performed at
50 K on a Bruker ELEXSYS E580Q-AWG (arbitrary waveform generator) pulse Q-
band spectrometer equipped with a 150W TWT ampliﬁer. A 4-pulse DEER
sequence with Gaussian, non-selective observer and pump pulses of 32 or 34 ns
length (corresponding to 14 or 16 ns FWHM) with 100MHz frequency separation
was used. Due to the coherent nature of the AWG generated pulses, a four-step
phase cycling (0–π/2–π–3/2π) of the pump pulse was performed together with 0–π
phase cycling of the observer pulses to remove unwanted effects of running echoes
from the DEER trace. The evaluation of the DEER data was performed using
DeerAnalysis201545. The background of the primary DEER traces was corrected
using stretched exponential functions with homogeneous dimensions of 1.8 to 3 for
different samples. A model-free Tikhonov regularization was used to extract
distance distributions from the background corrected form factors. The data of the
apo and ATP-EDTA states shown for the pairs 131TM288/248TM288 and 460TM287/
363TM288 in the absence of sybody are reproducible with respect to those
previously published9. Interspin distance simulations were performed with the
software MMM2015 using the MTSL ambient temperature library46,47.
Transport assay. L. lactis NZ9000 ΔlmrAΔlmrCD cells harboring the plasmids of
wild-type or mutant EfrEF were grown in M17 medium supplemented with 0.5%
glucose and 5 µg/ml chloramphenicol to an OD600 of 0.4–0.6 at 30 °C and the
expression was induced by adding a nisin-containing culture supernatant of L.
lactis NZ9700 for 2 h (1:1000 [v/v]). Cells were washed and resuspended using
ﬂuorescence buffer (50 mM KPi pH 7.0 and 5 mMMgSO4). Cells were diluted to an
OD600 of 0.5 and energized by adding 0.5% glucose. The accumulation of 5 µM
ethidium was monitored at 30 °C using a Fluorescence Spectrometer LS-55 (Perkin
Elmer, Schwerzenbach, Switzerland). Excitation and emission wavelengths (and slit
widths) were set at 520 nm (10 nm) and 595 nm (15 nm)16,17.
Reconstitution into proteoliposomes. E. coli polar lipids extracted from E. coli
total lipids (Avanti lipids 100500 P) and L-α-Phosphatidylcholine (from egg yolk,
Type XVI-E, ≥ 99% (TLC) P3556 Sigma) were dissolved in chloroform. Lipids were
mixed in a 3:1 (w/w) ratio, chloroform was evaporated and dried lipids were
dissolved in reconstitution buffer (50 mM K-HEPES pH 7.0). Lipids were sonicated
to generate small unilamellar vesicles (SUVs). SUVs were ﬂash-frozen in liquid
nitrogen and thawed four times to fuse the SUVs to large multilamellar vesicles
(LMVs). Large unilamellar vesicles (LUVs) were ﬁnally formed by extruding LMVs
through a 400 nm polycarbonate ﬁlter. LUVs were diluted to a working con-
centration of 4 mg/ml and destabilized using 5.25 mM Triton X-100. Detergent-
puriﬁed EfrEF variants were added to the destabilized liposomes at a protein:lipid
ratio of 1:100. Detergent molecules were removed by four rounds of adding and
removing 200 mg Bio-Beads (SM-2 polystyrene beads, Bio-Rad). Proteoliposomes
were harvested by centrifugation (40’000 rpm, 70 Ti rotor, Beckman) and resus-
pended in 50 mM K-HEPES pH 7.016.
Surface plasmon resonance. Binding afﬁnities were determined by surface plas-
mon resonance at 25 °C using a ProteOn™ XPR36 Protein Interaction Array System
(Biorad). Biotinylated TM287/288 variants were immobilized on ProteOn™ NLC
Sensor Chips at a density of 2000 RU. Nanobodies and sybodies expressed in
pSb_init were gel-ﬁltrated in 20 mM Tris-HCl pH 7.5 and 150 mM NaCl, and the
SPR measurements were carried out in the same buffer containing 0.015% (w/v) β-
DDM and either 1 mM MgCl2 or 1 mM MgCl2 and 0.5 mM ATP to measure
binding afﬁnities in the absence or presence of ATP, respectively. Every mea-
surement was done once and the data ﬁtted with a 1:1 interaction model using the
BioRad Proteon Analysis Software. In order to determine the half-lives of the OF
ATP-bound state of the different TM287/288 variants, all ﬁve biotinylated variants
were immobilized on a ProteOn™ NLC Sensor Chips at a density of 3000 RU. The
experiment was conducted in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.015% (w/
v) β-DDM, and 1 mMMgCl2 or 2.5 mM EDTA at 25 °C at a ﬂow-rate of 30 µl/min.
In order to charge the transporter variants with ATP-Mg or ATP-EDTA, buffer
containing 1 mM ATP together with either 1 mM MgCl2 or 2.5 mM EDTA was
injected at the beginning of the experiment.
Nanodisc preparation. Membrane scaffold protein MSP1E3D1 was subcloned
from pINITIAL (provided by Prof. Raimund Dutzler) into pBXNH3 (addgene:
Plasmid #47067) by FX cloning36. Freshly transformed MC1061 E. coli cells were
grown in Terriﬁc Broth (TB) medium supplemented 100 µg/ml ampicillin to an
OD600 of 1.0–1.5 at 37 °C and expression was induced by the addition of 0.0017%
(w/v) L-arabinose overnight at 22 °C. Cells were harvested, resuspended in lysis
buffer (20 mM Na-phosphate pH 7.4, 1% (v/v) Triton X-100 and 1 mM PMSF),
and disrupted with a M-110P Microﬂuidizer® (Microﬂuidics™). Cell debris were
pelleted at 8000 g for 30 min at 4 °C and the supernatant was loaded on a Ni-NTA
gravity ﬂow column equilibrated with lysis buffer, washed with 10 column volumes
buffer 1 (40 mM Tris-HCl pH 8.0, 0.3 M NaCl and 1% (v/v) Triton X-100), 10
column volumes buffer 2 (buffer 1+ 50 mM sodium cholate), 10 column volumes
buffer A (40 mM Tris-HCl pH 8.0 and 0.3 M NaCl), 10 column volumes buffer A
containing 20 mM imidazole, and ﬁnally eluted with 4 column volumes buffer A
containing 300 mM imidazole. 3 C protease was added (1:10 w/w) and the sample
dialyzed overnight at 4 °C against 20 mM Tris-HCl pH 7.5, 150 mM NaCl, and 0.5
mM K-EDTA. The next day, 2 mM MgCl2 were added to the sample, which was
then reloaded on a Ni-NTA gravity ﬂow column equilibrated with 20 mM Tris-HCl
pH 7.5, 150 mM NaCl, and 20 mM imidazole and eluted with two column volumes
using the same buffer. Buffer was exchanged by dialyzing three times against Tris-
HCl pH 7.5 and 0.5 mM K-EDTA for 1.5 h at room temperature. The puriﬁed
membrane scaffold protein was concentrated to 60 mg/ml using an Amicon Ultra-4
concentrator unit with a 10 kDa MWCO, ﬂash-frozen in liquid nitrogen, and
stored at −80 °C.
E. coli polar lipids (E. coli polar lipid extract, Avanti, 100600C) were mixed 3:1
(w/w) with L-α-phosphatidylcholine from egg yolk (Sigma, P3556) and chloroform
was evaporated. Dried lipids were dissolved in 20 mM HEPES pH 8.0, 0.5 mM K-
EDTA, 100 mM NaCl, and 100 mM cholate to a ﬁnal concentration of 38 mg/ml
(50 mM), and ﬁltered using a 0.22 µM ﬁlter. Lipids ready for nanodisc
reconstitutions were stored at −80 °C.
Puriﬁed, biotinylated TM287/288 variants solubilized in β-DDM were
reconstituted into nanodiscs using a 240:8:1 molar ratio of lipids:MSP1E3D1:
TM287/288. In order to spare membrane protein, the ideal lipid:MSP1E3D1
ratio was determined beforehand by reconstituting empty nanodiscs. Different
ratios were tested, ranging from 25:1 to 40:1 (lipid:MSP1E3D1). Empty
nanodiscs were loaded on a Superdex 200 Increase 10/300 GL (GE Healthcare)
column to separate empty nanodiscs from monomeric MSP1E3D1 and
aggregates. From the elution proﬁle the optimal lipid:MSP1E3D1 ratio of 30:1
was determined. The ﬁnal cholate concentration in the reconstitution mixture
was adjusted to 30 mM. The mixture was incubated at 25 °C for 20 min while
rocking at 650 rpm. Then, 200 mg bio-beads were added to 200 µl reconstitution
mixture, which was incubated overnight at 4 °C while rocking at 1000 rpm. Bio-
beads were removed using 0.1 µm PVDF spin-ﬁlters. Full nanodiscs were
separated from empty nanodiscs by gel ﬁltration using a Superdex 200 Increase
10/300 GL (GE Healthcare) equilibrated with 20 mM Tris-HCl pH 7.5 and 150
mM NaCl. The SEC proﬁle as well as a SDS-PAGE analysis of nanodisc-
reconstituted TM287/288 is shown in Supplementary Fig. 2c. TM287/288
variants reconstituted in nanodiscs were either immediately used or ﬂash-frozen
in liquid nitrogen and stored at −80 °C.
MD simulations. The simulation setup and parameters are equivalent to our
previous work11. In brief, all-atom MD simulations of TM287/288 embedded in an
explicitly solvated POPC bilayer were carried out with GROMACS48. It should be
noted that the source organism of TM287/288, the hyperthermophilic bacterium
Thermotoga maritima, has a unique lipid composition49, which is difﬁcult to
implement for MD simulations. For the simulations initiated from the IF structure
(PDB: 4Q4A), ATP-Mg was docked into the consensus site and D41TM287 and
D65TM288 were replaced by alanines. We conducted 20 individual simulations of
500 ns each (i.e., 10 μs in total) at 375 K. In addition, the OF state was simulated
starting from the crystal structure (PDB: 6QUZ) shown in Fig. 1a after removing
the sybody and replacing ATPγS by ATP. Furthermore, the same set of simulations
was carried out for the ATP-bound OF structure in which the 2xDtoA mutations
were introduced in silico (another 8 μs in total). In addition, the OF wild-type X-
ray structure was simulated in a POPE (instead of POPC) bilayer at 375 K (ten
simulations of 500 ns each, i.e., 5 μs in total).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
authors upon reasonable request. A reporting summary for this Article is available as
a Supplementary Information ﬁle. The source data underlying Figs. 2b, 4c, d, g and
Supplementary Figs. 2a, b are provided as a Source Data ﬁle. The coordinates of the
TM287/288 structures have been deposited under accession numbers 6QUZ (Sb_TM#35,
ATPγS-bound), 6QV0 (Sb_TM#35, ATP-bound), 6QV1 (Nb_TM#1) and 6QV2
(Nb_TM#2). Sybody Sb_TM#35 and nanobodies Nb_TM#1 and Nb_TM#2 will be
distributed for academic research upon reasonable request.
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